Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed about the change in role of Atul Tandon, Business Unit Head – Oncology. He will be transitioning from the said role with effect from close of business hours on July 31, 2023, as he takes up another responsibility within AstraZeneca group. In the interim, the Oncology Business Unit of the Company will be managed by Ayush Kumar Agarwal, who is currently the Director - Commercial Excellence.
The above information is a of company’s filings submitted to BSE.
